PPARGC1A and chronic kidney disease: In aggregate, the functional impacts of PGC‐1α in CKD have been conclusively demonstrated in preclinical studies, as PGC‐1α deficiency shows adverse effects, while genetic PGC‐1α overexpression or pharmacological PGC-1α upregulation is generally beneficial.